Breast Cancer Clinical Trial
Official title:
Parent Communication Study II - Randomized Controlled Trial of Decision Support vs. Education for Parent Communication of BRCA 1/2 Cancer Genetic Test Results to Children
RATIONALE: A study that evaluates the support of a decision guide used together with genetic
counseling may improve communication between mothers undergoing BRCA1/2 testing and their
minor-age children.
PURPOSE: This randomized phase III trial is studying standard genetic counseling given
together with a decision guide to see how well it works compared with genetic counseling
alone in improving communication between mothers undergoing BRCA1/2 testing and their
minor-age children.
OBJECTIVES:
Primary
- To evaluate the efficacy of a decision support intervention delivered in conjunction
with standard genetic counseling compared to standard genetic counseling alone in
improving communication between mothers undergoing BRCA1/2 testing and their minor-age
children.
Secondary
- To understand the mechanisms by which decision support impacts on decision outcomes.
- To identify mothers who are most and least likely to benefit from decision support.
- To explore the potential impact of decision support on disclosure and parent-child
psychosocial well-being.
OUTLINE: This is a multicenter study. Mothers are stratified according to their child's age
(< 13 vs ≥ 13 years old), child's gender (female vs male), and trial site. Mothers are
randomized to 1 of 2 arms.
- Arm I (standard genetic counseling with communication aid): Mothers undergo standard
pre-test genetic counseling and provide a blood sample for mutation analysis. Mothers
also receive a copy of "My Children, My Test Results," a detailed decision guide
developed to promote quality and informed decision making and outcomes, and provide
support to mothers regardless of whether or not they choose to communicate their
BRCA1/2 test results to their children.
- Arm II (standard genetic counseling alone): Mothers undergo standard pre-test genetic
counseling and provide a blood sample for mutation analysis. Mothers also receive a
copy of "Genetic Testing for Breast and Ovarian Cancer Risk: It's Your Choice"
containing information regarding family history of breast and ovarian cancer risks,
BRCA1/2 genes, risks and benefits of genetic testing, medical management options for
carriers, and considerations including family communication.
All mothers complete extensive family history assessments during their baseline interviews
and disclose if they have been diagnosed with cancer, length and type of treatments, and the
number of other relatives with a history of cancer. Mothers are assessed at baseline
(pre-test genetic counseling), post-genetic counseling after learning test results, and at 1
and 6 months post-genetic counseling by a 30-45 minute multi-item and multi-scale
self-report telephone survey. Genetic testing results are also submitted to this study. The
frequency (number), intensity (length in minutes), and content of participant-initiated
telephone contacts to genetic counselors to assess intervention reactivity; participants'
self-reported use of educational guides; and their satisfaction with the intervention will
be assessed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |